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ABSTRACT
Objectives: Low serum vitamin D levels have been
associated with risk for certain malignancies, but
studies have not directly analysed levels between
community oncology and primary care practices. The
purpose of this study was to compare serum vitamin D
levels in patients at a community oncology practice
with non-cancer patients at a primary care practice.
Design: Retrospective caseecontrol study. 25-
Hydroxyvitamin D levels were ordered for screening in
both cancer and non-cancer patients. Levels were
compared in univariate and multivariate analyses
adjusted for age, body mass index and season of blood
draw.
Setting: A community-based radiation oncology centre
and a community-based primary care practice: both
located in Northeastern Pennsylvania, USA.
Participants: 170 newly diagnosed cancer patients
referred for initial consultation at the community
oncology centre from 21 November 2008 to 18 May
2010, and 170 non-cancer patients of the primary care
practice who underwent screening for hypovitaminosis
D for the ﬁrst time from 1 January 2009 to 31
December 2009.
Primary and secondary outcome measures: The
primary outcome measure was mean serum vitamin D
level, and the secondary outcome measures were
frequencies of patients with vitamin D levels <20 ng/
ml and levels <30 ng/ml.
Results: The oncology patients had a signiﬁcantly
lower mean serum vitamin D level (24.9 ng/ml) relative
to a cohort of non-cancer primary care patients
(30.6 ng/ml, p<0.001) from the same geographical
region. The relationship retained signiﬁcance after
adjustment for age, body mass index and season of
blood draw in multivariate analysis (p¼0.001). Levels
<20 and <30 ng/ml were more frequent in the
oncology patients (OR (95% CI)¼2.59 (1.44 to 4.67)
and 2.04 (1.20 to 3.46), respectively) in multivariate
analysis.
Conclusions: Cancer patients were found to have low
vitamin D levels relative to a similar cohort of non-
cancer primary care patients from the same
geographical region.
INTRODUCTION
Vitamin D, obtained through the diet,
supplementation and sunlight, is converted
to 25-hydroxyvitamin D in the liver.
1
25-Hydroxyvitamin D is the major circulating
form of vitamin D and undergoes hydroxyl-
ation in the kidney to 1,25-dihydroxyvitamin
D, the most active metabolite.
1 Production of
1,25-dihydroxyvitamin D is tightly regulated
by the parathyroid glands in response to
calcium.
1 Levels of 25-hydroxyvitamin D are
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Open Access Researchrelatively stable and can be measured to determine the
vitamin D status of a patient.
1 However, the deﬁnition of
normal circulating vitamin D levels is debatable.
12
Values <20 ng/ml have been traditionally considered
deﬁcient (in accordance with the latest Institute of
Medicine guidelines), whereas values <30 ng/ml have
been suggested to be suboptimal.
1e7
Non-skeletal actions of vitamin D have gained interest
in research, particularly in the ﬁeld of oncology. Low
serum vitamin D levels have been associated with risk for
carcinomas of the breast, prostate and colon in epide-
miological studies.
1 8e11 Research dating back to
the 1980s has proposed that variations in cancer by
latitude may be associated with vitamin D through
differences in ultraviolet B exposure.
12e14 Subsequent
laboratory experiments have found that many cell types,
in addition to renal and intestinal cells, possess vitamin
D receptors and 25-hydroxyvitamin D 1-alpha-hydroxy-
lase, the cellular machinery required to metabolise
vitamin D.
191 5 e19 In vitro studies have further demon-
strated that vitamin D regulates genes involved with
cellular proliferation and differentiation.
191 6 e20 Taken
together, this body of evidence suggests a potential role
for vitamin D in the aetiology of cancer.
To date, studies have not directly compared vitamin D
levels in community oncology and primary care practices
in the same region. Analysing vitamin D levels in this
manner may elucidate trends not previously apparent.
Therefore, the purpose of this study was to compare
vitamin D levels in patients at a community oncology
practice with non-cancer patients at a primary care
practice.
MATERIALS AND METHODS
The study was a retrospective caseecontrol design, and
local institutional review board approval was obtained.
The cases (cancer patients) consisted of a consecutive
series of patients seen for initial radiation oncology
consultation from 21 November 2008 to 18 May 2010 at
a community-based oncology centre in Northeastern
Pennsylvania, USA. Serum 25-hydroxyvitamin D levels
were ordered at the initial visit. Data for the cases were
collected through a manual review of medical records.
The controls (primary care patients) were a random
sample of patients with no history of cancer who were
screened for the ﬁrst time for hypovitaminosis D from 1
January 2009 to 31 December 2009 at a community-
based primary care practice in Northeastern Pennsyl-
vania, USA. Data for the controls were obtained by
retrieval from an electronic health record. 25-hydroxy-
vitamin D levels were measured at outpatient laboratory
centres, and three major companies were retrospectively
identiﬁed: two using a chemiluminscent assay and one
using an enzyme immunoassay.
MYSTAT 12 (Systat Software Inc., Chicago, Illinois,
USA) and StatPlus 2009 Professional 5.8.4 (AnalystSoft
Inc., Alexandria, Virginia, USA) were used for statistical
analyses with signiﬁcance deﬁned as a<0.05. Origin 8.5
(OriginLab Corp., Northampton, Massachusetts, USA)
was used to generate histograms and best-ﬁt Gaussian
distributions. Student t test was performed to compare
vitamin D levels between oncology and non-cancer
patients. Multiple linear regression was used to adjust
the mean difference for age, body mass index (BMI) and
season of blood draw. In multiple linear regression,
vitamin D levels were set as the dependent variable
(continuous), and the independent variables were set as
caseecontrol status (dichotomous), age (continuous),
BMI (continuous) and season of blood draw (dichoto-
mous). The coefﬁcient for caseecontrol status repre-
sented the mean difference in serum vitamin D levels
between the oncology and primary care patients, after
adjustment for age, BMI and season of blood draw.
The prevalence of vitamin D deﬁciency (<20 ng/ml)
and vitamin D insufﬁciency (<30 ng/ml) were examined
with respect to caseecontrol status by calculating the OR
and computing Pearson’s c
2 test. Multiple logistic
regression was used to adjust associations for age, BMI
and season of blood draw. In multiple logistic regression
analyses, frequencies of patients with vitamin D levels less
than the cut-off value (20 or 30 ng/ml) were set as the
dependent variable (dichotomous) and the independent
variables were set as caseecontrol status (dichotomous),
age (continuous), BMI (continuous) and season of blood
draw (dichotomous). In all multivariate analyses, season
of blood draw was adjusted as a dichotomous variable
deﬁned as summer months (June, July or August) versus
all other months. Patients with missing data were
excluded from the multivariate analyses.
RESULTS
One hundred and seventy cancer patients had levels
drawn within 6 months of consultation at the community
radiation oncology centre. The most common primary
cancer sites were as follows: breast (40), prostate (35),
thyroid (25) and lung (12). The distribution of the
American Joint Committee on Cancer (AJCC) stages of
cancer was as follows: stage 0 (6), stage I (47), stage II
(52), stage III (32), stage IV (25) and unknown stage (8).
One hundred and seventy non-cancer patients screened
for hypovitaminosis D for the ﬁrst time had vitamin D
levels drawn at a large, community-based primary care
practice. The baseline patient characteristics are
outlined in table 1. The cancer patients were an average
of 6.8 years older (p<0.001), but both groups had
a similar mean BMI (p¼0.637). The frequency distribu-
tion of vitamin D levels in the primary care and oncology
groups is shown in ﬁgure 1.
The cancer patients had a signiﬁcantly lower mean
serum vitamin D level, and this relationship retained
signiﬁcance after adjustment for age, BMI and season of
blood draw. Table 1 outlines the unadjusted mean values
and adjusted mean difference of serum vitamin D levels
between cancer and non-cancer patients. The primary
care patients had a mean serum vitamin D level of
30.6 ng/ml, while the cancer patients had a mean serum
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Vitamin D levels in oncology and primary care patientsvitamin D level of 24.9 ng/ml (p<0.001). After adjust-
ment for age, BMI and season of blood draw, the mean
difference in serum vitamin D levels was 5.4 ng/ml
(p¼0.001).
Vitamin D deﬁciency, deﬁned as <20 ng/ml, was more
common in the oncology practice (OR (95% CI)¼2.39
(1.43 to 3.99), p¼0.001); vitamin D insufﬁciency,
deﬁned as <30 ng/ml, was also more common in the
oncology practice (OR (95% CI)¼ 2.32 (1.47 to 3.66),
p<0.001). The relationships retained signiﬁcance in
multivariate analysis after correction for age, BMI and
season of blood draw, as shown in table 1. Vitamin D
deﬁciency and vitamin D insufﬁciency were more
common in the oncology patients in multivariate analysis
(OR (95% CI)¼2.59 (1.44 to 4.67) and 2.04 (1.20 to
3.46), respectively).
DISCUSSION
While the deﬁnition of an acceptable range of serum
vitamin D levels is debatable,
1 2 patients seen at the
oncology clinic displayed signiﬁcantly reduced serum
levels of 25-hydroxyvitamin D relative to a geographically
similar group of non-cancer patients (table 1 and ﬁgure
1). While the primary care patients had a mean around
30 ng/ml, a value deemed sufﬁcient by many experts,
1
55% of patients fall below this value as indicated by the
positive skew in the histogram. The vitamin D levels in
oncology patients also display positive skew, with a visibly
lower mean of approximately 25 ng/ml. The combined
best-ﬁt Gaussian distribution curves illustrate a lower
distribution of vitamin D levels in the oncology patients
relative to the primary care patients.
The reduced serum vitamin D levels seen in the cancer
patients may be either a cause or effect relationship.
Multiple studies have found increased cancer risk in
individuals with decreased serum vitamin D levels and
may explain the association in our data.
1 8e11 However, it
is also possible that a diagnosis of cancer promotes
reduced vitamin D levels due to poor oral intake or
decreased sun exposure. Regardless of the mechanism,
these data suggest that increased clinical suspicion of
vitamin D deﬁciency in cancer patients may be reason-
able among the primary care community.
There are several limitations that should be consid-
ered while interpreting the data. First, the laboratory
used to determined 25-hydroxyvitamin D levels in both
the cancer patients and the non-cancer patients was not
controlled. Patients received orders for 25-hydrox-
yvitamin D and had levels drawn at outpatient laborato-
ries, most of which used either a chemiluminscent assay
or enzyme immunoassay for 25-hydroxyvitamin D deter-
mination. These two methods are thought to be
comparable in accuracy and precision.
21 Since patients
at either clinic resided in the same geographical loca-
tion, it is unlikely that there were important differences
in measurement of vitamin D between or within the
groups. Second, conditions that may affect vitamin D
Table 1 Baseline patient characteristics and serum vitamin D levels in oncology patients and non-cancer primary care patients
Oncology Primary care p Value OR (95% CI)*
Sample size (n) 170 170 ee
Age (6SD), years 63.3 (614.8) 56.5 (616.3) <0.001 e
BMI (6SD), kg/m
2 29.3 (67.1)y 28.9 (65.8) 0.637 e
Blood drawn in summer months, count (%) 44 (25.9) 31 (18.2) 0.089 e
Vitamin D levels
Mean (SD), ng/ml 24.9 (11.4) 30.6 (12.5) <0.001z e
Adjusted mean difference, ng/ml 5.4 0.001x e
Patients <30 ng/ml, count (%) 126 (74) 94 (55) 0.008* 2.04 (1.20 to 3.46)
Patients <20 ng/ml, count (%) 56 (33) 29 (17) 0.002* 2.59 (1.44 to 4.67)
BMI, body mass index.
*Multiple logistic regression adjusted for age, BMI and season of blood draw.
yBMI for cancer patients was based on data of 110 patients.
zStudent t test.
xMultiple linear regression adjusted for age, BMI and season of blood draw.
Figure 1 Frequency distribution of 25-hydroxyvitamin D
levels in primary care patients (dark grey bars) and oncology
patients (light grey bars). The mean (SD) vitamin D levels were
24.9 (11.4) ng/ml for oncology patients and 30.6 (12.5) ng/ml
for primary care patients. The best-ﬁt Gaussian distributions
are represented as a solid curve for oncology patients and
a dashed curve for the primary care patients.
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Vitamin D levels in oncology and primary care patientslevels, such as treatment in cancer patients or comorbid
conditions in primary care patients, were not accounted
for in the analysis. Third, BMI data were available for
only 110 of the 170 oncology patients. Since patients
with missing data were excluded from multivariate
analyses, the sample size was reduced among the
oncology patients. Finally, gender, supplement use and
race were not controlled for in the analysis, although the
vast majority of the patient pool was Caucasian.
Considering the limitations, there are several
strengths to the analysis. The oncology and primary care
practices serve the same geographical area; therefore,
latitude and regional trends were similar between the
groups. In addition, the cancer and non-cancer patients
had levels drawn during a similar time frame in 2009
(only 12 cancer patients had levels drawn outside of
2009). Thus, the reduced levels seen in the oncology
patients relative to the non-cancer patients were inde-
p e n d e n to fa g e ,B M I ,l a t i t u d e ,t i m ea n ds e a s o no fb l o o d
draw and geographical region. Finally, our data may
have practical relevance to physicians in private practice
since both of our patient populations were derived from
community-based practices.
CONCLUSIONS
Low levels of 25-hydroxyvitamin D were observed in both
the community oncology practice and the primary care
practice. However, the cancer patients had signiﬁcantly
lower levels of circulating vitamin D. A heightened
awareness for vitamin D deﬁciency among cancer patients
may be appropriate based on the results of this study.
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